检索结果 - Tsai, Max
- Showing 1 - 16 results of 16
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease 由 Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Pugh, Melissa, Ardayfio, Paul, Kielbasa, William
出版 2021Text -
11
-
12
-
13
A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationsh... 由 Goldsmith, Paul, Affinito, John, McCue, Maggie, Tsai, Max, Roepcke, Stefan, Xie, Jinhui, Gertsik, Lev, Macek, Thomas A.
出版 2017Text -
14
-
15
-
16
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients 由 Gilleen, James, Farah, Yakub, Davison, Cate, Kerins, Sarah, Valdearenas, Lorena, Uz, Tolga, Lahu, Gez, Tsai, Max, Ogrinc, Frank, Reichenberg, Avi, Williams, Steve C., Mehta, Mitul A., Shergill, Sukhi S.
出版 2018Text